However, tucatinib, in combination with trastuzumab and capecitabine, has shown promising clinical efficacy in patients with brain metastases, thus, we sought to evaluate the preclinical effect of tucatinib on the suppression of HER2-positive brain tumors. Here, ERBB2 is linked to brain neoplasm.